Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.61 |
| ▸ | ESRRG | P62508 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7296645 | 0.91 | HDAC3 (0.75) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL23352874 | 0.91 | HDAC3 (0.75) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL29817773 | 0.89 | MEN1 (0.67) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL2026427 | 0.89 | EPHX2 (0.56) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL29178161 | 0.89 | SMN1; SMN2 (0.64) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL11940935 | 0.87 | SMN1; SMN2 (0.61) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL15223378 | 0.86 | MEN1 (0.56) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL8218803 | 0.85 | NR1H4 (0.63) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL2730172 | 0.84 | MAPT (0.81) | NR1H4EPHX2MEN1MAPTKMT2A | |
| SCHEMBL13756246 | 0.84 | MAPT (0.81) | NR1H4EPHX2MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12351924-B2 | Electroreductive cross coupling | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| CN-113462278-B | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
| EP-0650955-B1 | Amine compound and electro-luminescence device comprising same | HODOGAYA CHEMICAL CO LTD (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5707747-A | CHARGE TRANSPORT COMPOUNDS | HODOGAYA CHEMICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5639914-A | DURABLE, STABLE, LOW VOLTAGE ELECTROLUMINESCENT EMITTERS | HODOGAYA CHEMICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0650955-A1 | Amine compound and electro-luminescence device comprising same | HODOGAYA CHEMICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | NR1H4 1667/4885EPHX2 3533/4885MEN1 1860/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | NR1H4 290/4885EPHX2 306/4885MEN1 186/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | NR1H4 290/4885EPHX2 306/4885MEN1 186/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | NR1H4 359/4885EPHX2 356/4885MEN1 180/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | NR1H4 290/4885EPHX2 306/4885MEN1 186/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | NR1H4 3962/4885EPHX2 4798/4885MEN1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.